<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023360</url>
  </required_header>
  <id_info>
    <org_study_id>200804034R</org_study_id>
    <nct_id>NCT01023360</nct_id>
  </id_info>
  <brief_title>Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP &amp; Platelet Mapping ™ Assay</brief_title>
  <official_title>Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP &amp; Platelet Mapping™ Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, drugs commonly used for antiplatelet are aspirin and clopidogrel when encountering
      stroke or coronary heart disease. In this study, we would use VASP assay and
      thromboelastograph with platelet mapping assay kit to evaluate the antiplatelet resistance in
      general population and the relationship between clopidogrel and proton pump inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intent is to search the standard to diagnose of the antiplatelet drug resistance
      and to discover the prevalence of drug resistance in Taiwanese population in Taiwan. The
      trial will enroll at least 30 healthy people after fulfilling the investigation
      questionnaire. All the participants will receive antiplatelet drugs in two separate period
      and measured the efficacy by VASP assay and thromboelastograph with platelet mapping assay.
      The health volunteer will receive clopidogrel and different types of proton pump inhibitor to
      see the interference of antiplatelet efficacy between each drug.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the antiplatelet drug response apparently shown in TEG &amp; Platelet mapping assay</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>30 Healthy People</condition>
  <arm_group>
    <arm_group_label>Clopidogrel and proton pump inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel and proton pump inhibitors</intervention_name>
    <description>baseline detection --&gt; clopidogrel 75 mg PO QD for 1 week --&gt; clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --&gt; clopidogrel 75 mg PO QD for 1 week (wash-out phase) --&gt; clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --&gt; clopidogrel 75 mg PO QD for 1 week (wash-out phase) --&gt; clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --&gt;
1 week washout --&gt; aspirin 100mg PO QD for 1 week</description>
    <arm_group_label>Clopidogrel and proton pump inhibitors</arm_group_label>
    <other_name>clopidogrel</other_name>
    <other_name>rabeprazole</other_name>
    <other_name>pantoprazole</other_name>
    <other_name>esomeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 Healthy people, without major systemic disease, not under medication treatment

        Exclusion Criteria:

          -  Systemic disease, under medication control with NSAID, anticoagulants, taking
             antiplatelet drugs before entering trial, Chinese herb, pregnant or breast feeding
             woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Tien Chiang, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu-Tien Chiang, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>62150</phone_ext>
    <email>futienc@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jen-Kuang Lee, MD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>62394</phone_ext>
    <email>jenkuang_lee@yahoo.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu-Tien Chiang, MD, PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>62150</phone_ext>
      <email>futienc@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Jen-Kuang Lee, MD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>62394</phone_ext>
      <email>jenkuang_lee@yahoo.com.tw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chiang Fu-Tien, PhD</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

